Liposomal daunorubicin

Liposomal daunorubicin is a chemotherapy drug that is FDA approved to treat AIDS-related Kaposi’s sarcoma. It is also commonly used to treat specific types of leukaemia and non-Hodgkin lymphoma. Liposomal daunorubicin is intravenously administered. It utilizes the liposomal carrier system that provides a favorable pharmacokinetic profile at the site of KS lesions resulting in a 10-fold increase in concentrations compared to that which is achieved with conventional preparations.

Trade name: DaunoXome®

• Cancerbackup Liposomal daunorubicin (DaunoXome®)
• Women&Cancer Magazine Liposomal daunorubicin
• Johns Hopkins AIDS Service – New from the Food and Drug Administration (FDA)

Template:WH Template:WS